Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure
NCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT Number: NCT03661060
To evaluate if Italian Cardiologists are treating Heart Failure (HF) patients according to International guidelines and if a structured educational program can improved their adherence.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ospedali Riuniti - Sod Cardiologia Ospedaliera Emod. E Utic, Ancona, AN, Italy
Multicentre, cross-sectional, prospective, non-interventional, observational study designed to evaluate the level of adherence to current ESC guidelines recommendations in both acute and chronic HF patients enrolled in each participating center and to verify if a specific HF educational intervention composed by an educational web based program of data collection and face to face meetings is able to improve adherence to guidelines recommendations evaluated during a second enrollment period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Enrollment
To assess number of patients managed and treated following the 2016 ESC Heart Failure Gudelines (acute HF, chronic HFrEF, chronic HFmrEF, chronic HFpEF).
Time frame: 24 months
Patients treatment in phase 1 versus phase 3
Time frame: 12 months Follow-up
Death from all-causes, for cardiovascular causes, for HF
Time frame: 12 months Follow-up
Hospital admissions from all-causes, for cardiovascular causes, for HF
Time frame: Enrollement
The rate of patients with chronic HFrEF with an indication to ICD and/or CRT planned in clinical practice
Time frame: Enrollment
The rate of patients with HFrEF receiving all the drugs recommended by current guidelines: ACE-Is/ARBs, betablockers and MRAs, in the absence of specific contraindications/intolerance.
Time frame: Enrollment
Rate of patients treated with oral anticoagulants in case of AF
Time frame: Enrollment
The rate of implementation of a new drug approach (ARNI) for patients with HF and EF ≤35%
Time frame: Enrollment
The rate of CHF patients with an available measure of EF and of creatinine.
Heart Care Foundation
Other
Acronym: BLITZ-HF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05806606
Behavior, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06847438
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07721909
Cardiovascular Diseases, Heart Diseases
Muscat, Oman
View Trial Details